Osiris Therapeutics (NASDAQ: OSIR) reported Q3 EPS of ($0.09), $0.05 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $2.15 million versus the consensus estimate of $1.89 million.

For earnings history and earnings-related data on Osiris Therapeutics (OSIR) click here.